HDL cholesterol response to GH replacement is associated with common cholesteryl ester transfer protein gene variation (-629C>A) and modified by glucocorticoid treatment

European Journal of Endocrinology

Volumn 162, Issue 2, 2010, Pages 227-234

  Dullaart, Robin P F ^a   Van Den Berg, Gerrit ^a   Van Der Knaap, Aafke M ^a   Dijck Brouwer, Janneke ^a   Dallinga Thie, Geesje M ^b   Zelissen, Peter M J ^c   Sluiter, Wim J ^a   Van Beek, André P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; CORTISONE ACETATE; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; APOLIPOPROTEIN E4 GENE; ARTICLE; CETP GENE; CHOLESTEROL BLOOD LEVEL; CORTICOTROPIN DEFICIENCY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; GROWTH HORMONE DEFICIENCY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADRENOCORTICOTROPIC HORMONE; ADULT; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; FEMALE; GENETIC VARIATION; GENOTYPE; GLUCOCORTICOIDS; HOMOZYGOTE; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC;

EID: 75149175267     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0742     Document Type: Article

References (46)

1. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC & Stewart PM. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001 357 425-431.
2. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T & Thorne M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. Journal of Clinical Endocrinology and Metabolism 1998 83 382-395.
3. Attanasio AF, Bates PC, Ho KK, Webb SM, Ross RJ, Strasburger CJ, Bouillon R, Crowe B, Selander K, Valle D, Lamberts SW & Hypopituitary Control and Complications Study International Advisory Board. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status - 3-year results from the HypoCCS Database. Journal of Clinical Endocrinology and Metabolism 2002 87 1600-1606.
4. Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, Goth MI, Wilton P & Koltowska-Haggstrom M. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. European Journal of Endocrinology 2006 155 79-90.
5. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML, Endocrine Society's Clinical Guidelines Subcommittee & Stephens PA. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2006 91 1621-1634.
6. Leese GP, Wallymahmed M, Wieringa G, VanHeyningen C & MacFarlane IA. Apo E phenotype and changes in serum lipids in adult patients during growth hormone replacement. European Journal of Endocrinology 1999 140 174-179.
7. Beentjes JA, van Tol A, Sluiter WJ & Dullaart RPF. Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults. Journal of Lipid Research 2000 41 925-932.
8. Carrilho AJ, Cunha-Neto MB, Nunes VS, Lottenberg AM, Medina WL, Nakandakare ER, Musolino NR, Bronstein MD & Quintao EC. Plasma cholesteryl ester transfer protein and lipoprotein levels during treatment of growth hormone-deficient adult humans. Lipids 2001 36 549-554.
9. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B & Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. Journal of Clinical Endocrinology and Metabolism 2004 89 2192-2199.
10. Attanasio AF, Lamberts SW, Matranga AM, Birkett MA, Bates PC, Valk NK, Hilsted J, Bengtsson BA & Strasburger CJ. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. Journal of Clinical Endocrinology and Metabolism 1997 82 82-88.
11. Tall AR. Plasma cholesteryl ester transfer protein. Journal of Lipid Research 1993 34 1255-1274.
12. Borggreve SE, de Vries R & Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. European Journal of Clinical Investigation 2003 33 1051-1069.
13. Dullaart RPF, Dallinga-Thie GM, Wolffenbuttel BHR & van Tol A. CETP inhibition in cardiovascular risk management: a critical appraisal. European Journal of Clinical Investigation 2007 37 90-98.
14. Boekholdt SM & Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. Journal of Lipid Research 2003 44 1080-1093.
15. Dullaart RPF & Sluiter WJ. Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. Pharmacogenomics 2008 9 747-763.
16. Dachet C, Poirier O, Cambien F, Chapman J & Rouis M. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 507-515.
17. Borggreve SE, Hillege HL, Wolffenbuttel BHR, de Jong PE, Bakker SJ, van der Steege G, van Tol A & Dullaart RPF. The effect of cholesteryl ester transfer protein -629C→A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. Journal of Clinical Endocrinology and Metabolism 2005 90 4198-4204.
18. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RPF, Keavney B, Ye Z & Danesh J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. Journal of the American Medical Association 2008 299 2777-2788.
19. Beentjes JAM, van Tol A, Sluiter WJ & Dullaart RPF. Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis 2000 153 491-498.
20. Beentjes JAM, van Tol A, Sluiter WJ & Dullaart RPF. Decreased plasma cholesterol esterification and cholesteryl ester transfer in hypopituitary patients on glucocorticoid replacement therapy. Scandinavian Journal of Clinical and Laboratory Investigation 2000 60 189-198.
21. Crown A & Lightman S.Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clinical Endocrinology 2005 63 483-492.
22. Dullaart RPF, Schols JL, van der Steege G, Zelissen PM, Sluiter WJ & van Beek AP. Glucocorticoid replacement is associated with hypertriglyceridaemia, elevated glucose and higher non-HDL cholesterol and may diminish the association of HDL cholesterol with the -629C>A CETP promoter polymorphism in GH-receiving hypopituitary patients. Clinical Endocrinology 2008 69 359-366.
23. Atger V, Leclerc T, Cambillau M, Guillemain R, Marti C, Moatti N & Girard A. Elevated high density lipoprotein concentrations in heart transplant recipients are related to impaired plasma cholesteryl ester transfer and hepatic lipase activity. Atherosclerosis 1993 103 29-41.
24. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD & Drosos AA. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthritis Research & Therapy 2006 8 R82.
25. García-Gómez C, Nolla JM, Valverde J, Narváez J, Corbella E & Pintó X. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. European Journal of Clinical Investigation 2008 38 686-692.
26. Dullaart RPF. Comment on high HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. European Journal of Clinical Investigation 2009 39 533.
27. Dullaart RPF, Pasterkamp SH, Beentjes JA & Sluiter WJ. Evaluation of adrenal function in patients with hypothalamic and pituitary disorders: comparison of serum cortisol, urinary free cortisol and the human-corticotrophin releasing hormone test with the insulin tolerance test. Clinical Endocrinology 1999 50 465-471.
28. Tjeerdsma G, Sluiter WJ, Hew JM, Molenaar WM, de Lange WE & Dullaart RPF. Hyperprolactinaemia is associated with a higher prevalence of pituitary-adrenal dysfunction in non-functioning pituitary macroadenoma. European Journal of Endocrinology 1996 135 299-308.
29. Lukaski HC & Johnson PE. A simple, inexpensive method of determining total body water using a tracer dose of D2O and infrared absorption of biological fluids. American Journal of Clinical Nutrition 1985 41 391-398.
30. Lopez-Virella M, Stone P, Ellis S & Colwell J. Cholesterol determination in high-density lipoproteins separated by three different methods. Clinical Chemistry 1977 23 882-884.
31. Reymer PW, Groenemeyer BE, van de Burg R & Kastelein JJ. Apolipoprotein E genotyping on agarose gels. Clinical Chemistry 1995 41 1046-1047.
32. Blaauwwiekel EE, Beusekamp BJ, Sluiter WJ, Hoogenberg K & Dullaart RPF. Apolipoprotein E genotype is a determinant of low-density lipoprotein cholesterol and of its response to a lowcholesterol diet in type 1 diabetic patients with elevated urinary albumin excretion. Diabetic Medicine 1998 15 1031-1035.
33. Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC & Loriaux DL. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. Journal of Clinical Endocrinology and Metabolism 1991 72 39-45.
34. Kraan GP, Dullaart RPF, Pratt JJ, Wolthers BG, Drayer NM & De Bruin R. The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. Journal of Clinical Endocrinology and Metabolism 1998 83 1247-1252.
35. Agha A & Monson JP. Modulation of glucocorticoid metabolism by the growth hormone-IGF1 axis. Clinical Endocrinology 2007 66 459-465.
36. Beentjes JA, Kerstens MN & Dullaart RPF. Effects of growth hormone replacement on cortisol metabolism in hypopituitary patients treated with cortisone acetate. Scandinavian Journal of Clinical and Laboratory Investigation 2001 61 277-286.
37. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A & Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. Journal of Clinical Endocrinology and Metabolism 2006 91 3954-3961.
38. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007 370 1829-1839.
39. Hargrove GM, Junco A & Wong NC. Hormonal regulation of apolipoprotein AI. Journal of Molecular Endocrinology 1999 22 103-111.
40. Berg AL & Nilsson-Ehle P. Direct effects of corticotropin on plasma lipoprotein metabolism in man - studies in vivo and in vitro. Metabolism 1994 43 90-97.
41. Jansen H, van Tol A, Auwerx J, Skretting G & Staels B. Opposite regulation of hepatic lipase and lecithin: cholesterol acyltransferase by glucocorticoids in rats. Biochimica et Biophysica Acta 1992 1128 181-185.
42. Talmud PJ & Humphries SE. Gene:environment interaction in lipid metabolism and effect on coronary heart disease risk. Current Opinion in Lipidology 2002 13 149-154.
43. Martin LJ, Connelly PW, Nancoo D,Wood N, Zhang ZJ, Maguire G, Quinet E, Tall AR, Marcel YL & McPherson R. Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in men: relationship to apolipoprotein E genotype. Journal of Lipid Research 1993 34 437-446.
44. Johannsson G, Oscarsson J, Rosén T, Wiklund O, Olsson G, Wilhelmsen L & Bengtsson B-Å. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. Arteriosclerosis, Thrombosis, and Vascular Biology 1995 15 2142-2150.
45. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R,Wiman B, de Faire U & Danesh J. Association of apolipoprotein E genotypes with lipid levels and coronary risk. Journal of the American Medical Association 2007 29 1300-1311.
46. Borggreve SE, Hillege HL, Wolffenbuttel BHR, de Jong PE, Zuurman MW, van der Steege G, van Tol A & Dullaart RPF. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. Journal of Clinical Endocrinology and Metabolism 2006 91 3382-3388.